Genetics of the epilepsies: where are we and where are we going?
Genetics of the epilepsies: where are we and where are we going?
复制标题
DOI:
10.1097/wco.0b013e32835ee6ff
复制
发表时间:
2013-04
影响因子:
4.8
通讯作者:
Lowenstein DH
中科院分区:
文献类型:
--
作者:
Helbig I;Lowenstein DH
We aim to review the most recent advances in the field of epilepsy genetics with particular focus on the progress in gene discovery in monogenic epilepsies, identification of risk genes in complex genetic epilepsies and recent findings in the field of epilepsy pharmacogenomics. During the last 12 months, the use of massive parallel sequencing technologies has allowed for the discovery of several genes for monogenic epilepsies. Most importantly, PRRT2 was identified as the long-sought gene for Benign Familial Infantile Seizures (BFIS). Mutations in KCNT1 were found in two seemingly unrelated monogenic epilepsies including Malignant Migrating Partial Seizures of Infancy (MMPSI) and severe Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE). A genome-wide association study in Idiopathic Generalized Epilepsy (IGE) revealed the first common risk variants for human seizure disorders including variants in VRK2, PNPO and SCN1A. Furthermore, a landmark study provided evidence that screening for the HLAB*1502 variant may prevent carbamazepine-induced side effects in the Taiwanese population. Also, HLA-A*3101 variants were identified as a risk factor for carbamazepine side effects in Europeans. Novel technologies and an unprecedented level of international collaboration has resulted in novel genes for monogenic and complex genetic epilepsies as well as risk factors for side effects of antiepileptic drugs. This review provides an overview of the most relevant studies in the last year and highlights the future direction of the field.